BR112015022624A2 - regime de dose, e, método para tratamento de aterosclerose - Google Patents
regime de dose, e, método para tratamento de ateroscleroseInfo
- Publication number
- BR112015022624A2 BR112015022624A2 BR112015022624A BR112015022624A BR112015022624A2 BR 112015022624 A2 BR112015022624 A2 BR 112015022624A2 BR 112015022624 A BR112015022624 A BR 112015022624A BR 112015022624 A BR112015022624 A BR 112015022624A BR 112015022624 A2 BR112015022624 A2 BR 112015022624A2
- Authority
- BR
- Brazil
- Prior art keywords
- apo
- treatment cycle
- treating atherosclerosis
- dose regimen
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
1 / 1 resumo âregime de dose, e, mãtodo para tratamento de ateroscleroseâ essa invenã§ã£o fornece regimes de dosagens e mã©todos para tratamento de aterosclerose com uma quantidade eficaz de um mimã©tico de apo e para fornecer efeitos terapãªuticos sustentados mesmo apã³s a retirada do tratamento. os regimes de dosagens e mã©todos envolvem um ciclo de tratamento seguido por uma fase de repouso em que o paciente ã© administrado com uma quantidade eficaz de um mimã©tico de apo e durante o ciclo de tratamento e sem mimã©tico de apo e durante a fase de repouso. o ciclo de tratamento e a fase de repouso podem variar.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361782956P | 2013-03-14 | 2013-03-14 | |
US201361834992P | 2013-06-14 | 2013-06-14 | |
PCT/US2014/027719 WO2014152776A1 (en) | 2013-03-14 | 2014-03-14 | Apolipoprotein mimetics and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015022624A2 true BR112015022624A2 (pt) | 2017-10-31 |
Family
ID=51581312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022624A BR112015022624A2 (pt) | 2013-03-14 | 2014-03-14 | regime de dose, e, método para tratamento de aterosclerose |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160002315A1 (pt) |
EP (1) | EP2996706B1 (pt) |
JP (2) | JP6570511B2 (pt) |
AU (2) | AU2014239186B2 (pt) |
BR (1) | BR112015022624A2 (pt) |
CA (1) | CA2903869A1 (pt) |
DK (1) | DK2996706T3 (pt) |
ES (1) | ES2753381T3 (pt) |
IL (1) | IL240787B (pt) |
MX (1) | MX2015012818A (pt) |
NZ (1) | NZ713291A (pt) |
WO (1) | WO2014152776A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016018665A1 (en) | 2014-07-31 | 2016-02-04 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
WO2017120568A1 (en) * | 2016-01-08 | 2017-07-13 | Lipimetix Development, Inc. | Apoe mimetic peptide compositions |
MX2018009680A (es) * | 2016-02-17 | 2018-09-10 | Regeneron Pharma | Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
US5631280A (en) | 1995-03-29 | 1997-05-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6506880B2 (en) | 1998-03-17 | 2003-01-14 | The Uab Research Foundation | Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol |
US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
AU2008296487A1 (en) * | 2007-08-28 | 2009-03-12 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
EP2521564B1 (en) * | 2010-01-06 | 2016-11-16 | Cognosci, Inc. | Apoe peptide dimers and uses thereof |
WO2016018665A1 (en) * | 2014-07-31 | 2016-02-04 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
-
2014
- 2014-03-14 DK DK14769489.7T patent/DK2996706T3/da active
- 2014-03-14 BR BR112015022624A patent/BR112015022624A2/pt not_active Application Discontinuation
- 2014-03-14 JP JP2016502527A patent/JP6570511B2/ja not_active Expired - Fee Related
- 2014-03-14 CA CA2903869A patent/CA2903869A1/en not_active Abandoned
- 2014-03-14 EP EP14769489.7A patent/EP2996706B1/en active Active
- 2014-03-14 US US14/770,270 patent/US20160002315A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027719 patent/WO2014152776A1/en active Application Filing
- 2014-03-14 ES ES14769489T patent/ES2753381T3/es active Active
- 2014-03-14 AU AU2014239186A patent/AU2014239186B2/en not_active Ceased
- 2014-03-14 NZ NZ713291A patent/NZ713291A/en not_active IP Right Cessation
- 2014-03-14 MX MX2015012818A patent/MX2015012818A/es active IP Right Grant
-
2015
- 2015-08-24 IL IL240787A patent/IL240787B/en active IP Right Grant
-
2017
- 2017-06-09 AU AU2017203911A patent/AU2017203911B2/en active Active
-
2019
- 2019-02-18 JP JP2019026743A patent/JP6772317B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6772317B2 (ja) | 2020-10-21 |
EP2996706A1 (en) | 2016-03-23 |
AU2017203911B2 (en) | 2019-03-07 |
NZ713291A (en) | 2017-04-28 |
JP2019089834A (ja) | 2019-06-13 |
EP2996706A4 (en) | 2017-01-18 |
AU2017203911A1 (en) | 2017-06-29 |
JP6570511B2 (ja) | 2019-09-04 |
DK2996706T3 (da) | 2019-10-21 |
CA2903869A1 (en) | 2014-09-25 |
MX2015012818A (es) | 2016-05-12 |
EP2996706B1 (en) | 2019-07-31 |
IL240787B (en) | 2019-07-31 |
WO2014152776A1 (en) | 2014-09-25 |
US20160002315A1 (en) | 2016-01-07 |
JP2016515137A (ja) | 2016-05-26 |
ES2753381T3 (es) | 2020-04-08 |
AU2014239186A1 (en) | 2015-10-08 |
IL240787A0 (en) | 2015-10-29 |
AU2014239186B2 (en) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
MX2022013172A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
BR112015023725A2 (pt) | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme | |
BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
BR112018014850A2 (pt) | dispositivo de injeção usável | |
NZ629332A (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
PE20151374A1 (es) | Regimen de dosificacion de un sedante | |
BR112017021383A2 (pt) | regime de dosagem para doses omitidas de ésteres de paliperidona injetáveis de longa ação | |
BR112017000556A2 (pt) | terapia de combinação para câncer | |
BR112015022624A2 (pt) | regime de dose, e, método para tratamento de aterosclerose | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
BR112014011223A8 (pt) | Método de tratar uma doença proliferativa | |
BR112015022513A2 (pt) | produto e método para tratamento de diarreia | |
UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
MX2016007370A (es) | Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: UAB RESEARCH FOUNDATION (US) , LIPIMETIX DEVELOPME |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |